Biomea Fusion, Inc. (BMEA)

12.35 +0.42 (+3.52%) At close: 04:00PM EDT

Biomea Fusion, Inc.

900 Middlefield Road
4th Floor
Redwood City, CA 94063
United States
650 980 9099
https://biomeafusion.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 103

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Thomas Andrew Butler	Co-Founder, Chairman & CEO	950.41k	N/A	1981
Mr. Ramses M. Erdtmann	Co-Founder, President, COO & Director	N/A	N/A	1963
Mr. Franco Valle	CFO & Principal Accounting Officer	673.66k	N/A	1981
Caroline Perez- Dupont	Senior Vice President of Contracts	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Corporate governance

Biomea Fusion, Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.